Atai life sciences announces first participant dosed in phase 1b trial of vls-01

New york and berlin, march 04, 2024 (globe newswire) -- atai life sciences (nasdaq: atai) (“atai” or “company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the first healthy participant has been dosed in the phase 1b trial of vls-01, an oral transmucosal film (otf) formulation of n,n-dimethyltryptamine (dmt).
ATAI Ratings Summary
ATAI Quant Ranking